# EDGAR Filing Document

**Accession Number:** 0001374339
**File Stem:** 0001178913-25-003546
**Filing Date:** 2025-10
**Character Count:** 15179
**Document Hash:** facca0e8552e2c0c4ce32ed43d349174
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-25-003546.hdr.sgml**: 20251023

**ACCESSION NUMBER**: 0001178913-25-003546

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251023

**DATE AS OF CHANGE**: 20251023

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ProMIS Neurosciences Inc.
- **CENTRAL INDEX KEY:** 0001374339
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93797
- **FILM NUMBER:** 251411275

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2
- **BUSINESS PHONE:** 416-847-6898

**MAIL ADDRESS:**
- **STREET 1:** SUITE 200, 1920 YONGE STREET
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4S 3E2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMORFIX LIFE SCIENCES LTD
- **DATE OF NAME CHANGE:** 20060831
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SPHERA FUNDS MANAGEMENT LTD.
- **CENTRAL INDEX KEY:** 0001496201

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 4 ITZHAK SADE BUILDING A
- **STREET 2:** 29TH FLOOR
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6777520
- **BUSINESS PHONE:** 972-3-6845535

**MAIL ADDRESS:**
- **STREET 1:** 4 ITZHAK SADE BUILDING A
- **STREET 2:** 29TH FLOOR
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6777520

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Issuer:** ProMIS Neurosciences Inc.

**Title of Class of Securities:** Common Shares, no par value per share

**CUSIP Number:** 74346M406

**Date of Event Which Requires Filing of this Statement:** 09/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Sphera Funds Management Ltd. | Names of Reporting Persons<br>Sphera Funds Management Ltd. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>L3 | Citizenship or Place of Organization<br>L3 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>3122090 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>3122090 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3122090 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3122090 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.51% | Percent of Class Represented by Amount in Row (9)<br>5.51% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Percentage reported in Item 11 is based on 53,811,110 Common Shares outstanding as of September 26, 2025 (as provided by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (the "SEC") on October 3, 2025) and 2,826,903 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.

---

| 1. | Names of Reporting Persons<br>Sphera Global Healthcare GP Ltd. | Names of Reporting Persons<br>Sphera Global Healthcare GP Ltd. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>L3 | Citizenship or Place of Organization<br>L3 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>3122090 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>3122090 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3122090 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3122090 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.51% | Percent of Class Represented by Amount in Row (9)<br>5.51% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Percentage reported in Item 11 is based on 53,811,110 Common Shares outstanding as of September 26, 2025 (as provided by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the SEC on October 3, 2025) and 2,826,903 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.

---

| 1. | Names of Reporting Persons<br>Sphera Global Healthcare Management LP. | Names of Reporting Persons<br>Sphera Global Healthcare Management LP. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>L3 | Citizenship or Place of Organization<br>L3 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>3122090 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>3122090 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3122090 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3122090 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.51% | Percent of Class Represented by Amount in Row (9)<br>5.51% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** Percentage reported in Item 11 is based on 53,811,110 Common Shares outstanding as of September 26, 2025 (as provided by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the SEC on October 3, 2025) and 2,826,903 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.

---

**Item 1(a). Name of Issuer:**
ProMIS Neurosciences Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada, M4S 3E2

**Item 2(a). Name of Person Filing:**
Sphera Funds Management Ltd.
Sphera Global Healthcare GP Ltd.
Sphera Global Healthcare Management LP

**Item 2(b). Address of Principal Business Office:**
Address of the Principal Business Office of each of the reporting persons is: 4 Itzhak Sade, Building A, 29th Floor, Tel Aviv 6777504, Israel

**Item 2(c). Citizenship:**
Each of the reporting person is organized under the laws of the State of Israel

**Item 2(d). Title of Class of Securities:**
Common Shares, no par value per share

**Item 2(e). CUSIP Number:**
74346M406

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

See row 9 of cover page of each reporting person.
The securities reported herein by Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP are beneficially owned as follows:
*	511,875 warrants, with each warrant currently exercisable into one Common Share, representing a total of 0.90% of the total Common Shares outstanding are held directly by Sphera Global Healthcare Master Fund, which has delegated its investment management authority to Sphera Global Healthcare Management LP (the "Management Company").
*	295,187 Common Shares and 2,315,028 warrants, with each warrant currently exercisable into one Common Share, together representing a total of 4.61% of the total Common Shares outstanding, are held directly by Sphera Biotech Master Fund, L.P., which has delegated its investment management authority to the Management Company.
The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd., the shares of which are owned 90% by Sphera Funds Management Ltd.
This Statement shall not be construed as an admission by any of the Reporting Persons that it is the beneficial owner of any of the securities covered by this Statement, and each Reporting Person disclaims beneficial ownership of any such securities. In addition, the Reporting Persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the Reporting Persons and other entities named in this Schedule 13G disclaims the existence of any such group.

**(b) Percent of class:**

Incorporated by reference to Item 11 of the cover page for each reporting person.
Percentage reported in Item 11 for each reporting person is based on 53,811,110 Common Shares outstanding as of September 26, 2025 (as provided by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the SEC on October 3, 2025) and 2,826,903 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

Incorporated by reference to Item 5 of the cover page for each reporting person.

**(ii) Shared power to vote or to direct the vote:**

Incorporated by reference to Item 6 of the cover page for each reporting person. See also note in Item 4(a) above.

**(iii) Sole power to dispose or to direct the disposition of:**

Incorporated by reference to Item 7 of the cover page for each reporting person.

**(iv) Shared power to dispose or to direct the disposition of:**

Incorporated by reference to Item 8 of the cover page for each reporting person. See also note in Item 4(a) above.

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Sphera Funds Management Ltd.**

**Date:** 10/23/2025

**By:** /s/ Adi Hanetz

**Name & Title:** Adi Hanetz / General Counsel

**Sphera Global Healthcare GP Ltd.**

**Date:** 10/23/2025

**By:** /s/ Adi Hanetz

**Name & Title:** Adi Hanetz / General Counsel

**Sphera Global Healthcare Management LP.**

**Date:** 10/23/2025

**By:** /s/ Adi Hanetz

**Name & Title:** Adi Hanetz / General Counsel